Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing is based on halted Phase III trial showing overall survival of 44 percent in patients with hepatocellular carcinoma treated with sorafenib.
You may also be interested in...
Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
As Nexavar’s Oncology Potential Grows, So Do Bayer’s Sales Predictions
Firm says the kidney cancer drug’s additional indications in liver cancer and potentially other cancers will raise peak sales beyond €500 million.